Abstract:
Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
Abstract:
Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
Abstract:
Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
Abstract:
Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
Abstract:
Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
Abstract:
Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
Abstract:
The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to :0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications.
Abstract:
The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to 1:0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications. (FIG. 6).
Abstract:
The present disclosure is generally directed to enzymes and in particular beta-glucosidase variants. Also described are nucleic acids encoding beta-glucosidase variants, compositions comprising beta-glucosidase variants, methods of using beta-glucosidase variants, and methods of identifying additional useful beta-glucosidase variants.
Abstract:
Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.